Eric's mailing address filed with the SEC is 1 North End Ave, New York, NY 10282, USA.
Over the last 21 years, insiders at Immutep have traded over $3,152,820 worth of Immutep stock and bought 15,000 units worth $128,330 . The most active insiders traders include Kon Fung Chan, Frederick W Wackerle, and Levi Hong Kaye Lee. On average, Immutep executives and independent directors trade stock every 132 days with the average trade being worth of $138,215. The most recent stock trade was executed by Frederick W Wackerle on 17 November 2005, trading 10,000 units of IMMP stock currently worth $65,800.
immutep is a globally active biotechnology company, listed on the australian stock exchange and on the nasdaq global market in the us. as a leader in personalized bio-therapeutic products for cancer, immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. immutep's main pipeline of products is based on the lag-3 immune control mechanism which plays a vital role in the regulation of the t cell immune response. the most clinically advanced product is a t cell immunostimulatory factor (apc activator), imp321, for cancer chemoimmunotherapy which has completed early phase ii trials. a number of additional lag-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.
Immutep executives and other stock owners filed with the SEC include: